Shots: Nora collaborates with a biopharmaceutical partner to obtain the commercial rights for a biosimilar drug The collaboration will support both private insurers and public formularies by reducing the costs […]readmore
Tags : canada
Shots: Celltrion launches the world’s first SC formulation of infliximab (120mg, q2w, fd, as a pre-filled pen (auto-injector) in Canada for the treatment of adult patients with RA Remsima SC […]readmore
Shots: The companies enter into a license agreement for the Preserflo MicroShunt superseding the previous collaboration between the two parties Glaukos get exclusive commercialization rights for the MicroShunt in the […]readmore
Shots: The company expands its portfolio with the marketing of the 6th biosimilars in Canada. Inclunox and Inclunox HP (enoxaparin sodium solution for injection) is indicated for use in 6 […]readmore
Shots: Valeo has started commercial shipment of Redesca and Redesca HP, its low molecular weight heparin (“LMWH”) biosimilar across Canada The LMWH is being used primarily for treating and preventing […]readmore
Shots: Samsung Bioepis in collaboration with Merck broadens its global reach by launching Hadlima in Australia for multiple autoimmune diseases With the launch in Australia, Samsung Bioepis’ adalimumab is now […]readmore
Biosimilars
Fresenius Kabi Launches Idacio (biosimilar, adalimumab) for Multiple Chronic Inflammatory
Shots: Health Canada has authorized Idacio on Oct 30, 2020, for marketing in Canada and is now available for all indications of the reference (Humira) in the field of rheumatology, […]readmore
Shots: Health Canada has approved Hulio, a biosimilar referencing AbbVie’s Humira (adalimumab), which is now available in Canada. It is licensed from Fujifilm Kyowa Kirin and approved for all adalimumab […]readmore
Shots: The company expands its portfolio with the marketing of the 5th biosimilars in Canada. Hyrimoz is indicated for use in nine indications of the reference (Humira) in the field […]readmore
Shots: The Health Canada has granted a NOC which is based on clinical evidence for Remsima/CT-P13 SC vs CT-P13 IV up to 1year in patients with RA. The results demonstrated […]readmore